10. Stelara

Stelara
Johnson & Johnson's Stelara notched and FDA approval to treat ulcerative colitis—its second GI approval—in October. (Johnson & Johnson)

Stelara
Company: Johnson & Johnson
Used for: Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis
2019 sales: $4.35 billion

Johnson & Johnson's stalwart immunology blockbuster Stelara has been a steady earner for years. But with some areas of its portfolio lagging behind, J&J is hoping that pushing Stelara into new markets can help overcome those stumbles—and keep Stelara generating significant sales for years to come. 

Stelara could add around $800 million in sales to its 2019 haul of $4.35 billion, bringing its 2020 sales total to around $5.15 billion in 2020, according to EvaluatePharma. 

Most of that growth will ultimately be tied to Stelara's FDA nod in October to treat ulcerative colitis—the med's first new approval in two years. 

RELATED: J&J's Stelara clinches ulcerative colitis nod to back up declining Remicade

10. Stelara